Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: Long-term follow-up results

Urologia Internationalis

Volumn 60, Issue SUPPL.2, 1998, Pages 18-24

  Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Leuprorelin acetate; LHRH analogues; Prostate cancer; Three month depot

Indexed keywords

HYPOTHALAMUS RELEASING FACTOR; LEUPRORELIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL;

EID: 0031977869     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056547     Document Type: Conference Paper

References (22)

1. Wirth M: Therapie des lokal begrenzten Prostatakarzinoms; in Rubben H (ed): Uro-Onkologie, ed 2. Berlin, Springer, 1997, pp 294-339.
2. Lepor H, Kimball AW, Walsh PC: Cause-specific actuarial survival analysis: A useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 1989;141:82-84.
3. American Cancer Society: Guidelines for the cancer-related health checkup: Recommendations and rationale. CA 1980;30:194.
4. Catalona W, Smith D, Ratcliff T, Dodds KM, Coplen DE, Juan JJJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
5. Dijkman GA, Debruyne FMJ: Epidemiology of prostate cancer. Eur Urol 1996;30:281-295.
6. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JS, for the Zoladex Study Group: Independent prognostic factors in patients with metastatic (Stage D2) prostate cancer. JAMA 1991;265:618-621.
7. Villavicencio H: Quality of life of patients with advanced and metastatic prostate carcinoma. Eur Urol 1993;24(suppl 2):118-121.
8. Eckart O, Tunn UW, Lübben G, Kienle E: Leuprorelinacetat 3-Monats-Depot: Ein neues galenisches Prinzip eines bewährten GnRH-Analogons zur Behandlung des Prostatakarzinoms. Akt Urol 1996;5:281-286.
9. Fornara P, Jocham D: Klinische Ergebnisse einer Studie mit einer neuen Formulierung von Leuprorelinacetat 3-Monats-Depot zur Behandlung des fortgeschrittenen Prostatakarzinoms. J Urol Urogynäkol 1996;3:19-25.
10. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996;30:7-14.
11. Rohl HF, Beuke HP: Effect of orchiectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992;26:11-14.
12. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD: Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973;45:668-677.
13. Del Moral PF, Dijkman GA, Debruyne FMJ, Witjes WPJ, Kolvenbag GJCM, for the Dutch South East Cooperative Urological Group: Three-month depot of goserelin acetate: Clinical efficacy and endocrine profile. Urology 1996;48:894-900.
14. Ryan PG, Peeling WB: UK trials of treatment for M1 prostatic cancer. Am J Clin Oncol 1988;11:169-172.
15. Debruyne FM, Dijkman GA, Lee DCH, Witjes WPJ, on behalf of the Dutch South East Cooperative Urological Group: A new long acting formulation of the luteinizmg hormone-releasing hormone analogue, goserelin: Results of studies in prostate cancer. J Urol 1996;155;1352-1354.
16. Di Silverio F, Serio M, D'Eramo GD, Sciarra F: Zoladex versus Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: A multicenter Italian study. Eur J Urol 1990;18:54-61.
17. Kienle E, Lübben G, the German Leuprolide Study Group: Efficacy and safety of leuprorelin acetate depot for prostate cancer. Ural Int 1996;56:23-30.
18. Denis NJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M: Goserelin acetate und flutamide versus bilateraler orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-129.
19. Crawford ED, Eisenberger MA, McLeod DG, Wilding G, Blumenstein BA: Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adenocarcinoma of the prostate (CaP): Results of NC1 intergroup study 0105 (SWOG and ECOG). J Urol 1997;157:336. Abst 1311.
20. De Voogt HJ, Adenauer H, Widdra WG: The use of the LHRH-analogue buserelin in the treatment of prostatic carcinoma. Scand J Urol Nephrol 1991;138:131-136.
21. Iversen P, Rasmussen F, Klarskow P, Christensen IJ, for the Danish Prostatic Cancer Group: Long-term results of Danish prostatic cancer group trial 86. Cancer 1993;72:3851-3854.
22. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-508.